The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).
 
Manish A. Shah
Consulting or Advisory Role - Lilly; Sanofi
Research Funding - Bayer/Onyx (Inst); Genentech (Inst); Sanofi (Inst)
 
Jae Yong Cho
No Relationships to Disclose
 
Iain Tan Bee Huat
No Relationships to Disclose
 
Niall C. Tebbutt
No Relationships to Disclose
 
Chia-Jui Yen
No Relationships to Disclose
 
Alice Kang
Employment - Roche
 
David S. Shames
Employment - Roche/Genentech
 
Lilian Bu
Employment - Roche
 
Yoon-Koo Kang
Honoraria - Bayer; Novartis; Roche; Sanofi
Consulting or Advisory Role - Bayer; Novartis; Roche; Sanofi
Research Funding - Bayer; Novartis; Roche; Sanofi